Global Odevixibat Market Strategic Research Report

Scope of the Report

The global Odevixibat market size is predicted to grow from US$ 176 million in 2025 to US$ 427 million in 2032; it is expected to grow at a CAGR of 9.0% from 2026 to 2032.

In 2025, global odevixibat production reached approximately 120,000 units..Odevixibat is an orally administered small-molecule ileal bile acid transport (IBAT) inhibitor used for the treatment of rare cholestatic liver diseases. The drug works by selectively inhibiting the reabsorption of bile acids in the ileum, thereby reducing the accumulation of bile acids in the liver and bloodstream, decreasing intrahepatic cholestasis, alleviating symptoms such as pruritus, and improving liver function parameters. Odevixibat is primarily indicated for diseases such as progressive familial intrahepatic cholestasis (PFIC) and is an important targeted therapy in the field of rare diseases. It has been approved in multiple countries and regions for the treatment of pediatric patients and individuals with rare cholestatic liver disorders.

Odevixibat (brand name Bylvay), as the first oral IBAT inhibitor, is primarily used for the treatment of rare cholestatic liver diseases such as progressive familial intrahepatic cholestasis (PFIC), and is positioned within the rapidly growing rare disease therapeutics market. In recent years, driven by improved diagnosis rates of rare liver diseases, expansion of pediatric indications, and increasing demand for targeted therapies, this class of innovative drugs has demonstrated strong growth potential. Odevixibat has gradually achieved commercial penetration in Europe, the United States, and certain emerging markets, owing to its non-systemic mechanism of action and favorable efficacy in relieving pruritus symptoms. However, due to the extremely small patient population, the overall market size remains limited, and it also faces competition from other IBAT inhibitors and alternative treatments for cholestasis. Therefore, its future market growth will largely depend on indication expansion (such as ALGS), broader market access, and accumulation of long-term clinical data.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Odevixibat market?

What factors are driving Odevixibat market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Odevixibat market opportunities vary by end market size?

How does Odevixibat break out by Type, by Application?

This report presents a comprehensive overview of the global Odevixibat market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

• 1.2 mg capsules
• 0.6 mg capsules
• 200 mcg Granules
• 600 mcg Granules

Segment by Combination Therapy

• Combination of Odevixibat and Bile Acid Sequestrants
• Combination of Odevixibat and Hepatoprotective Agents

Segment by Sales Channels

• Hospital
• Retail
• Online

Segment by Production Technology

• Originator
• Generic

Segment by Application

• Progressive Familial Intrahepatic Cholestasis (PFIC)
• Alagille Syndrome (ALGS)
• Cholestatic Pruritus in Children and Adults
• Biliary Atresia & Other Rare Cholestatic Liver Diseases 提供一些关于Biliary Atresia的研究论文 奥维昔巴特（Odevixibat）的作用机制是什么？ 奥维昔巴特（Odevixibat）的推荐剂量是多少？
• Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Odevixibat market:

• Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
• Distributors, channel partners and end users in Progressive Familial Intrahepatic Cholestasis (PFIC), Alagille Syndrome (ALGS), Cholestatic Pruritus in Children and Adults evaluating demand and sourcing options
• Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
• Government agencies, industry associations and research institutions tracking industry developments and policy impact